Novel methods of type 1 diabetes treatment.

Abstract

Type 1 diabetes is an autoimmune disease characterized by the cell-mediated destruction of insulin-producing β-cells, leading to impaired glucose homeostasis, insulin insufficiency, and other complications. Although classic genetic studies have linked numerous genes to the susceptibility of developing diabetes, the mechanisms by which they influence the disease course remain poorly understood. Epigenetics, inheritable changes in gene expression that occur without accompanying genetic mutation, can both serve as a link between the environment and genetic causes of disease and help explain some of the observed vagaries of diabetes. Elucidation of the epigenetic landscape as it relates to putative treatment modalities is highly warranted. Drugs with histone deacetylase activity are in clinical trials for cancer and certain inflammatory diseases with high safety profiles and they hold similar promise for amelioration of type 1 diabetes with diminished secondary complications. Full-fledged studies on the epigenetics of type 1 diabetes are highly likely to provide novel tools for the manipulation of the disease in the years to come. In this review, epigenetic regulation mediated by small molecular inhibitors of histone deacetylases and their potential for preventing diabetes are discussed. Insights into the nature of the genetic mechanisms unraveled by these studies are also highlighted.

• Authors: Sundararajan Jayaraman
• Journal: Discovery medicine (Discov Med) Vol. 17 Issue 96 Pg. 347-55 (Jun 2014) ISSN: 1944-7930 [Electronic] United States
• PMID: 24979255 (Publication Type: Journal Article, Review)

Chemical References

• Histones
• Small Molecule Libraries

Topics

• DNA Methylation (drug effects, genetics)
• Diabetes Mellitus, Type 1 (drug therapy, genetics, therapy)
• Epigenesis, Genetic (drug effects)
• Genome, Human (genetics)
• Histones (metabolism)
• Humans
• Small Molecule Libraries (pharmacology, therapeutic use)